Total Payments
$3,658
2024 Payments
$2,067
Companies
36
Transactions
114
Medicare Patients
14,864
Medicare Billing
$2.4M
Payment Breakdown by Category
Food & Beverage$1,957 (53.5%)
Other$1,496 (40.9%)
Education$206.20 (5.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,957 | 95 | 53.5% |
| Long term medical supply or device loan | $1,496 | 15 | 40.9% |
| Education | $206.20 | 4 | 5.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,597 | 22 | $0 (2024) |
| ABBVIE INC. | $265.70 | 10 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $257.33 | 13 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $140.07 | 3 | $0 (2023) |
| Janssen Biotech, Inc. | $106.19 | 3 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $103.80 | 4 | $0 (2024) |
| GlaxoSmithKline, LLC. | $97.47 | 5 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $96.59 | 6 | $0 (2024) |
| Myriad Genetic Laboratories, Inc. | $92.58 | 3 | $0 (2022) |
| Daiichi Sankyo Inc. | $91.17 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,067 | 60 | Novartis Pharmaceuticals Corporation ($925.73) |
| 2023 | $991.15 | 35 | Novartis Pharmaceuticals Corporation ($367.67) |
| 2022 | $522.23 | 14 | Novartis Pharmaceuticals Corporation ($303.79) |
| 2021 | $24.67 | 2 | Global Blood Therapeutics, Inc. ($12.75) |
| 2018 | $28.40 | 2 | Gilead Sciences, Inc. ($16.11) |
| 2017 | $24.91 | 1 | Bayer HealthCare Pharmaceuticals Inc. ($24.91) |
All Payment Transactions
114 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $27.05 | General |
| Category: Oncology | ||||||
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | IMJUDO (Biological) | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $25.59 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/06/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $15.62 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $21.16 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 10/30/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.38 | General |
| Category: Oncology | ||||||
| 10/28/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $15.81 | General |
| Category: Oncology | ||||||
| 10/25/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $22.39 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/24/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $30.02 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 10/04/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $27.43 | General |
| Category: NONE | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 09/23/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.60 | General |
| Category: Oncology | ||||||
| 09/20/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2024 | AstraZeneca Pharmaceuticals LP | IMJUDO (Biological) | Food and Beverage | In-kind items and services | $25.44 | General |
| Category: Oncology | ||||||
| 09/02/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $40.19 | General |
| Category: Oncology | ||||||
| 08/27/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $32.48 | General |
| Category: Oncology | ||||||
| 08/23/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 08/23/2024 | AstraZeneca Pharmaceuticals LP | IMJUDO (Biological) | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: Oncology | ||||||
| 08/22/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $12.15 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Education | In-kind items and services | $83.99 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $25.04 | General |
| Category: NONE | ||||||
| 07/31/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 65 | 3,912 | 65,445 | $4.1M | $1.0M |
| 2022 | 64 | 3,662 | 28,333 | $2.7M | $686,746 |
| 2021 | 57 | 3,587 | 13,247 | $1.5M | $406,006 |
| 2020 | 54 | 3,703 | 12,328 | $1.3M | $320,371 |
Total Patients
14,864
Total Services
119,353
Medicare Billing
$2.4M
Procedure Codes
240
All Medicare Procedures & Services
240 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 21 | 16,400 | $2.2M | $709,486 | 31.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 370 | 1,367 | $341,750 | $84,859 | 24.8% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 36 | 41 | $196,882 | $45,456 | 23.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 64 | 221 | $156,247 | $21,328 | 13.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 88 | 182 | $66,976 | $17,307 | 25.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 364 | 1,869 | $37,380 | $15,700 | 42.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 367 | 1,502 | $96,128 | $15,510 | 16.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 362 | 1,635 | $58,860 | $12,424 | 21.1% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 62 | 73 | $77,891 | $11,964 | 15.4% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 19 | 32 | $55,104 | $11,589 | 21.0% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 159 | 355 | $45,440 | $7,238 | 15.9% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 44 | 51 | $33,507 | $4,617 | 13.8% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 202 | 780 | $24,180 | $4,597 | 19.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 44 | 96 | $30,048 | $4,378 | 14.6% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 72 | 85 | $69,785 | $4,345 | 6.2% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 18 | 11,730 | $58,650 | $4,322 | 7.4% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 39 | 465 | $26,040 | $4,238 | 16.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 27 | 56 | $13,832 | $3,331 | 24.1% |
| 85055 | Reticulated (young) platelet measurement | Office | 2023 | 41 | 95 | $13,585 | $3,328 | 24.5% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 29 | 54 | $18,576 | $2,573 | 13.8% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 47 | 52 | $35,672 | $2,498 | 7.0% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 20 | 36 | $9,504 | $2,405 | 25.3% |
| 82232 | Beta-2 microglobulin (protein) level | Office | 2023 | 35 | 147 | $14,112 | $2,331 | 16.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 17 | $11,798 | $2,258 | 19.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 44 | 103 | $16,171 | $2,234 | 13.8% |
About Dr. Larry Frase, M.D
Dr. Larry Frase, M.D is a Medical Oncology healthcare provider based in Longview, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942242995.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Larry Frase, M.D has received a total of $3,658 in payments from pharmaceutical and medical device companies, with $2,067 received in 2024. These payments were reported across 114 transactions from 36 companies. The most common payment nature is "Food and Beverage" ($1,957).
As a Medicare-enrolled provider, Frase has provided services to 14,864 Medicare beneficiaries, totaling 119,353 services with total Medicare billing of $2.4M. Data is available for 4 years (2020–2023), covering 240 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Longview, TX
- Active Since 06/12/2006
- Last Updated 05/02/2008
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1942242995
Products in Payments
- KISQALI (Drug) $1,216
- IMBRUVICA (Drug) $298.28
- IMJUDO (Biological) $181.46
- EPKINLY (Drug) $107.49
- OPDIVO (Biological) $83.04
- TECVAYLI (Biological) $79.74
- XT CDX (Device) $72.11
- Enhertu (Drug) $69.22
- myRisk (Device) $60.91
- KEYTRUDA (Biological) $60.22
- Stivarga (Drug) $59.36
- LIBTAYO (Biological) $54.10
- FOTIVDA (Drug) $52.77
- AYVAKIT (Drug) $48.62
- KRAZATI (Drug) $44.38
- MONJUVI (Drug) $43.02
- ZEPZELCA (Drug) $41.96
- Doptelet (Drug) $40.94
- JEMPERLI (Biological) $38.98
- IMFINZI (Biological) $34.47
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Longview
Dr. Rama Koya, Md, MD
Medical Oncology — Payments: $7,038
Medical Oncology $7,038
Dr. Neeraj Sharma, Md, MD
Medical Oncology — Payments: $4,347
Medical Oncology $4,347
Dr. Willard Andes, Md, MD
Medical Oncology — Payments: $326.41
Medical Oncology $326.41
Dr. Lewis Duncan, M.d, M.D
Medical Oncology — Payments: $60.99
Medical Oncology $60.99